Royal Perth Hospital

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Retrieved on: 
Thursday, September 15, 2022
Medical Devices, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Cardiology, FDA, Artery, Hank, University of Michigan, Population, POWER, Lithotripsy, Interventional cardiology, Industry, Generalized arterial calcification of infancy, Patient, CEO, State university system, BS, MBA, Technology, IVL, Royal Perth Hospital, AVS, Pennsylvania Hospital, Board of directors, Hillrom, PULSE, Dominican Republic, Pulse, Calcium, Board, Moyamoya disease, Elective surgery, Boston Scientific, Virginia Tech, Leg, University, Pharmaceutical industry, Medical imaging

AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.

Key Points: 
  • AVS is only the second company to conduct a first-in-human study in the rapidly growing intravascular lithotripsy space.
  • AVS is the first company to develop pulsatile intravascular lithotripsy, a therapy that is delivered through a balloon-based platform called PULSE.
  • We are excited by this first-in-human trial milestone we have achieved, added Mark Toland, President and Chief Executive Officer of AVS.
  • Kucheman added, I am delighted to join the AVS board and look forward to helping patients with limited treatment options.

Alucent Biomedical Announces First Patient Enrolled in First In Human Natural Vascular Scaffolding Clinical Trial

Retrieved on: 
Tuesday, April 12, 2022
Health, Medical Devices, Surgery, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Prince of Wales Hospital, Doppler ultrasonography, Flinders Medical Centre, Royal Perth Hospital, Angioplasty, Peripheral artery disease, Freedom, Patient, Technology, PAD, The Alfred Hospital, Safety, Quality of life, Vascular disease, Medical device

announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .

Key Points: 
  • announced that it has enrolled the first patient in ACTIVATE II, an Australia-based First-in-Human clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (AlucentNVS) technology .
  • The first patient in the ACTIVATE II study was enrolled by Dr. Chris Delaney at Flinders Medical Centre in Adelaide.
  • Alucent Biomedical is a privately held company dedicated to developing and commercializing its breakthrough Natural Vascular Scaffolding (AlucentNVS) technology for the treatment of vascular disease.
  • Alucent Biomedical was founded by the Avera Research Institute, part of the multistate Avera Health System, in 2017.

AVROBIO to Present Clinical and Preclinical Data at the 14th ICIEM Conference

Retrieved on: 
Monday, November 8, 2021
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Safety, University, University of Manchester, Industry, Private Securities Litigation Reform Act, Gaucher, Royal Perth Hospital, Clinical trial, Glycogen storage disease, Security (finance), Compte rendu, Department, Growth, Phrase, COVID-19, Glycogen storage disease type II, Cystinosis, Twitter, U.S. Securities and Exchange Commission, LinkedIn, Nephrology, International Congress on Tuberculosis, Lists of diseases, Royal Melbourne Hospital, Poster, Nasdaq, Patient, AVRO, Risk, Hunter syndrome, Brain, Data collection, Pharmaceutical industry

Clinical and preclinical data from the companys pipeline of lysosomal disorder programs will be included in one oral presentation and two poster presentations.

Key Points: 
  • Clinical and preclinical data from the companys pipeline of lysosomal disorder programs will be included in one oral presentation and two poster presentations.
  • Additionally, AVROBIO will sponsor a symposium on Advancing the patient experience during ex vivo lentiviral gene therapy for lysosomal disorders, chaired by Prof.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.
  • AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

AVROBIO Reports New Interim Safety Data Across Investigational Gene Therapies for Fabry and Gaucher Disease Type 1

Retrieved on: 
Tuesday, October 19, 2021
Health, Infectious Diseases, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Busulfan, European Society of Gene and Cell Therapy, Twitter, Haematopoietic system, B cell, Security (finance), Adult, Safety, Patient, University, Febrile neutropenia, Industry, ESGCT, Dehydration, Molecular biology, Cystinosis, Clinical trial, AES, Risk, Private Securities Litigation Reform Act, COVID-19, Glycogen storage disease, Kidney, Toxicity, Collection, LinkedIn, Department, Nasdaq, Glycogen storage disease type II, Hunter syndrome, Biomarker, Royal Perth Hospital, TCI, Mackay, Nausea, U.S. Securities and Exchange Commission, Fabry disease, Phrase, Growth, Disease, Brain, Vomiting, DNA, Șaeș, AVRO, Gene, Cell, Data collection, Fever, Lists of diseases, Inflammation, Gaucher's disease, Bone marrow, Pharmaceutical industry, Medical device, Vaccine

We believe the data shared this week continue to support the predictable safety profile of our investigational gene therapies targeting lysosomal disorders.

Key Points: 
  • We believe the data shared this week continue to support the predictable safety profile of our investigational gene therapies targeting lysosomal disorders.
  • Safety data from the ninth patient recently dosed in the FAB-GT study are still being analyzed, but preliminary data are consistent with the overall safety profile.
  • Overall, we believe that these data further support the risk-benefit profile of AVROBIOs investigational gene therapy for Fabry disease.
  • Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease.

AVROBIO to Present New Clinical and Preclinical Data Across Multiple Programs at the ESGCT 28th Annual Congress

Retrieved on: 
Wednesday, October 6, 2021
Biotechnology, Genetics, Health, Clinical Trials, Clinical trial, Compte rendu, Security (finance), Hunter syndrome, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Cystinosis, Patient, Time-invariant system, Glycogen storage disease, LinkedIn, Gene, Phrase, Twitter, Industry, University, Program, Lists of diseases, Growth, European Society of Gene and Cell Therapy, Glycogen storage disease type II, Risk, Cell, COVID-19, Research, Brain, Department, AVRO, Safety, Data collection, Nasdaq, Royal Perth Hospital, University of Manchester, ESGCT, Pharmaceutical industry

Clinical and preclinical data from across the companys pipeline of lysosomal disorder gene therapy programs will be included in two oral presentations and five poster presentations.

Key Points: 
  • Clinical and preclinical data from across the companys pipeline of lysosomal disorder gene therapy programs will be included in two oral presentations and five poster presentations.
  • The presentations are listed below, and the full program is available online at the ESGCT website .
  • AVROBIO is powered by our industry-leading plato gene therapy platform, our foundation designed to deliver gene therapy worldwide.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.